Cargando…

Cellular and Molecular Effects of Eribulin in Preclinical Models of Hematologic Neoplasms

SIMPLE SUMMARY: Hematologic neoplasms comprise a heterogeneous group of diseases that interfere with normal blood production. Treating patients who fail available therapies for these diseases is an ongoing challenge. Thus, the search for new treatment options is urgent, and drug repositioning is eme...

Descripción completa

Detalles Bibliográficos
Autores principales:	Vicari, Hugo Passos, Lima, Keli, Costa-Lotufo, Leticia Veras, Machado-Neto, João Agostinho
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9776580/ https://www.ncbi.nlm.nih.gov/pubmed/36551566 http://dx.doi.org/10.3390/cancers14246080

Ejemplares similares

PB1826: CELLULAR AND MOLECULAR CHARACTERIZATION OF THE ANTINEOPLASTIC EFFECTS OF CEPHALOCHROMIN IN MODELS OF ACUTE MYELOID LEUKEMIA
por: Nascimento, Mariane Cristina Do, et al.
Publicado: (2023)

Reversine exhibits antineoplastic activity in JAK2(V617F)-positive myeloproliferative neoplasms
por: Lima, Keli, et al.
Publicado: (2019)

Targeting glioma cells by antineoplastic activity of reversine
por: Hirakata, Camila, et al.
Publicado: (2021)

Exploring redox vulnerabilities in JAK2(V617F)-positive cellular models
por: Lima, Keli, et al.
Publicado: (2021)

P347: PHARMACOLOGICAL EZRIN INHIBITION REDUCES GROWTH, ADHESION, MIGRATION AND REGULATE GENE RELATED TO APOPTOSIS AND CELL CYCLE IN ACUTE LYMPHOBLASTIC LEUKAEMIA
por: Carlos Lipreri Da Silva, Jean, et al.
Publicado: (2023)

Obatoclax reduces cell viability of acute myeloid leukemia cell lines independently of their sensitivity to venetoclax
por: Lima, Keli, et al.
Publicado: (2022)

Preclinical activity of selinexor in combination with eribulin in uterine leiomyosarcoma
por: Mittal, Sonam, et al.
Publicado: (2023)

Preclinical Development of Seriniquinones as Selective Dermcidin Modulators for the Treatment of Melanoma
por: Hirata, Amanda S., et al.
Publicado: (2022)

Hematologic Neoplasms Associated with Down Syndrome: Cellular and Molecular Heterogeneity of the Diseases
por: Peroni, Edoardo, et al.
Publicado: (2023)

Stathmin 1 expression in plasma cell neoplasms
por: Machado-Neto, João Agostinho, et al.
Publicado: (2017)

miRNAs as prognostic predictors in acute myeloid leukemia
por: Machado-Neto, João Agostinho, et al.
Publicado: (2023)

Marine drugs for cancer: surfacing biotechnological innovations from the oceans
por: Jimenez, Paula Christine, et al.
Publicado: (2018)

Cellular Therapies for the Treatment of Hematological Malignancies; Swine Are an Ideal Preclinical Model
por: Duran-Struuck, Raimon, et al.
Publicado: (2019)

Integrating mechanisms of response and resistance against the tubulin binding agent Eribulin in preclinical models of osteosarcoma
por: Sampson, Valerie B., et al.
Publicado: (2016)

Eribulin drug review
por: Shetty, Nishitha, et al.
Publicado: (2014)

Eribulin in Cancer Treatment
por: Swami, Umang, et al.
Publicado: (2015)

Data mining in acute myeloid leukemia: identification of disease biomarkers, prognostic factors, novel targets, and potential drugs
por: Machado-Neto, João Agostinho, et al.
Publicado: (2023)

Seriniquinones as Therapeutic Leads for Treatment of BRAF and NRAS Mutant Melanomas
por: Hirata, Amanda S., et al.
Publicado: (2021)

Eribulin mesylate reduces tumor microenvironment abnormality by vascular remodeling in preclinical human breast cancer models
por: Funahashi, Yasuhiro, et al.
Publicado: (2014)

Emerging functions for ANKHD1 in cancer-related signaling pathways and cellular processes
por: de Almeida, Bruna Oliveira, et al.
Publicado: (2020)

Autoimmune Complications in Hematologic Neoplasms
por: Barcellini, Wilma, et al.
Publicado: (2021)

Clinical and molecular profile of a Brazilian cohort of patients with classical BCR-ABL1-negative myeloproliferative neoplasms
por: Porto-Soares, Moysés Antonio, et al.
Publicado: (2020)

Somatic mutations of calreticulin in a Brazilian cohort of patients with myeloproliferative neoplasms
por: Machado-Neto, João Agostinho, et al.
Publicado: (2015)

Malignant Adenomyoepithelioma of the Breast and Responsiveness to Eribulin
por: Lee, Suee, et al.
Publicado: (2015)

Efficacy of Eribulin in Soft Tissue Sarcomas
por: Phillips, Edward, et al.
Publicado: (2022)

The clinical and molecular diversity of mast cell leukemia with or without associated hematologic neoplasm
por: Jawhar, Mohamad, et al.
Publicado: (2017)

Dermatological manifestations of hematologic neoplasms. Part I: secondary specific skin lesions()
por: Souza, Patricia Karla de, et al.
Publicado: (2023)

Suppression of multiple anti‐apoptotic BCL2 family proteins recapitulates the effects of JAK2 inhibitors in JAK2V617F driven myeloproliferative neoplasms
por: Takei, Hisashi, et al.
Publicado: (2021)

NT157 exerts antineoplastic activity by targeting JNK and AXL signaling in lung cancer cells
por: de Miranda, Lívia Bassani Lins, et al.
Publicado: (2022)

The Hematology of Tomorrow Is Here—Preclinical Models Are Not: Cell Therapy for Hematological Malignancies
por: Arranz, Lorena
Publicado: (2022)

A randomized trial of eribulin monotherapy versus eribulin plus anlotinib in patients with locally recurrent or metastatic breast cancer
por: Liu, B., et al.
Publicado: (2023)

Liposome-Encapsulated Eribulin Shows Enhanced Antitumor Activity over Eribulin for Combination Therapy with Anti–PD-1 Antibody
por: Niwa, Yuki, et al.
Publicado: (2023)

The role of JAK2 abnormalities in hematologic neoplasms
por: Alabdulaali, Mohammed K.
Publicado: (2009)

The Clinical Characteristics of ARDS in Children With Hematological Neoplasms
por: Zhang, Qiao, et al.
Publicado: (2021)

High-Throughput CRISPR Screening in Hematological Neoplasms
por: Ancos-Pintado, Raquel, et al.
Publicado: (2022)

Dermatological manifestations of hematologic neoplasms. Part II: nonspecific skin lesions/paraneoplastic diseases()
por: de Souza, Patricia Karla, et al.
Publicado: (2023)

Molecular Pathways in Clonal Hematopoiesis: From the Acquisition of Somatic Mutations to Transformation into Hematologic Neoplasm
por: Gaulin, Charles, et al.
Publicado: (2022)

Eribulin mesylate in the treatment of metastatic breast cancer
por: Jain, Sarika, et al.
Publicado: (2012)

An α-chloroaldehyde-based formal synthesis of eribulin
por: Kaghad, Anissa, et al.
Publicado: (2023)

Eribulin in pretreated metastatic breast cancer patients: results of the TROTTER trial—a multicenter retrospective study of eribulin in real life
por: Garrone, Ornella, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_rklll9g04i35r3o8ptofrvc212